ABSORB
Device
Abbott Laboratories
Total Payments
$3.3M
Transactions
1,076
Doctors
55
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.0M | 442 | 39 |
| 2019 | $1.7M | 628 | 30 |
| 2018 | $538,674 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.2M | 892 | 96.8% |
| Consulting Fee | $99,675 | 108 | 3.1% |
| Food and Beverage | $4,363 | 71 | 0.1% |
| Travel and Lodging | $1,103 | 5 | 0.0% |
Payments by Type
Research
$3.2M
892 transactions
General
$105,141
184 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions. | Abbott Laboratories | $1.5M | 0 |
| ABSORB III Randomized Controlled Trial (RCT) (ABSORB-III) | Abbott Laboratories | $958,143 | 1 |
| Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial | Abbott Laboratories | $600,000 | 0 |
| Cardiovascular Events Following Non-Cardiac Surgery in Patients with and without Fluoropolymer DES I | Abbott Laboratories | $32,541 | 0 |
| Long-term Outcomes and Resource Utilization Associated with Target vessel Failure | Abbott Laboratories | $32,101 | 0 |
| Side Branch FFR After Provisional Stenting (ORBID-FFR) | Abbott Laboratories | $20,032 | 0 |
| A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions | Abbott Laboratories | $4,025 | 0 |
| Vascular Closure for Cardiac Ablation Registry (VACCAR) | Abbott Laboratories | $4,000 | 0 |
| CER_Dragonfly Optis Imaging Catheters | Abbott Laboratories | $3,900 | 1 |
Top Doctors Receiving Payments for ABSORB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Baltimore, MD | $3.1M | 885 |
| , MD | Cardiovascular Disease | Glencoe, MN | $20,188 | 4 |
| , M.D | Cardiovascular Disease | New Brunswick, NJ | $18,200 | 16 |
| , M.D | Cardiovascular Disease | New York, NY | $14,575 | 14 |
| , MD | Cardiovascular Disease | Brooklyn, NY | $11,000 | 11 |
| , MD | Cardiovascular Disease | New York, NY | $10,000 | 10 |
| , M.D | Cardiovascular Disease | New York, NY | $8,475 | 9 |
| Alejandro Torres | Pediatric Cardiology | New York, NY | $8,200 | 9 |
| , M.D | Internal Medicine | New York, NY | $8,200 | 9 |
| , M.D | Cardiovascular Disease | New York, NY | $7,000 | 7 |
| , M.D | Cardiovascular Disease | Cooperstown, NY | $5,000 | 5 |
| , M.D | Cardiovascular Disease | New York, NY | $5,000 | 5 |
| , M.D | Cardiovascular Disease | Mountain View, CA | $3,900 | 3 |
| , MD | Interventional Cardiology | Newark, DE | $3,350 | 5 |
| , MD | Cardiovascular Disease | Cleveland, OH | $1,116 | 7 |
| , MD | Cardiovascular Disease | Oklahoma City, OK | $803.29 | 15 |
| , MD | Vascular Surgery | Los Angeles, CA | $484.29 | 7 |
| , MD | Cardiovascular Disease | New York, NY | $202.77 | 4 |
| , MD | Cardiovascular Disease | Brockton, MA | $200.00 | 3 |
| , M.D | Internal Medicine | Boston, MA | $200.00 | 3 |
| , D.O | Vascular & Interventional Radiology | Oklahoma City, OK | $177.56 | 1 |
| , D.O | Surgery | Oklahoma City, OK | $177.55 | 1 |
| , M.D | Cardiovascular Disease | Cincinnati, OH | $175.00 | 1 |
| , M.D | Diagnostic Radiology | Dallas, TX | $149.56 | 1 |
| , DO | Interventional Cardiology | New York, NY | $149.27 | 1 |
Ad
Manufacturing Companies
- Abbott Laboratories $3.3M
Product Information
- Type Device
- Total Payments $3.3M
- Total Doctors 55
- Transactions 1,076
About ABSORB
ABSORB is a device associated with $3.3M in payments to 55 healthcare providers, recorded across 1,076 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2018 to 2020. In 2020, $1.0M was paid across 442 transactions to 39 doctors.
The most common payment nature for ABSORB is "Unspecified" ($3.2M, 96.8% of total).
ABSORB is associated with 9 research studies, including "A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions." ($1.5M).